Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study(*) (2019)
- Authors:
- Autor USP: PEREIRA, JULIANA - FM
- Unidade: FM
- DOI: 10.1080/10428194.2017.1321750
- Subjects: LINFOMA; SOBREVIDA; ANTINEOPLÁSICOS
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Leukemia & lymphoma
- ISSN: 1042-8194
- Volume/Número/Paginação/Ano: v. 60, n. 1, p. 172-179, 2019
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: hybrid
- Licença: cc-by-nc-nd
-
ABNT
ROBAK, Tadeusz et al. Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study(*). Leukemia & lymphoma, v. 60, n. 1, p. 172-179, 2019Tradução . . Disponível em: https://doi.org/10.1080/10428194.2017.1321750. Acesso em: 24 abr. 2024. -
APA
Robak, T., Huang, H., Jin, J., Zhu, J., Liu, T., Samoilova, O., et al. (2019). Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study(*). Leukemia & lymphoma, 60( 1), 172-179. doi:10.1080/10428194.2017.1321750 -
NLM
Robak T, Huang H, Jin J, Zhu J, Liu T, Samoilova O, Pylypenko H, Verhoef G, Siritanaratkul N, Osmanov E, Pereira J. Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study(*) [Internet]. Leukemia & lymphoma. 2019 ; 60( 1): 172-179.[citado 2024 abr. 24 ] Available from: https://doi.org/10.1080/10428194.2017.1321750 -
Vancouver
Robak T, Huang H, Jin J, Zhu J, Liu T, Samoilova O, Pylypenko H, Verhoef G, Siritanaratkul N, Osmanov E, Pereira J. Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study(*) [Internet]. Leukemia & lymphoma. 2019 ; 60( 1): 172-179.[citado 2024 abr. 24 ] Available from: https://doi.org/10.1080/10428194.2017.1321750 - CD4+ lymphocytes in asymptomatic HTLV-1 carriers present cell cycle arrest in GO/G1 phase
- Expression of CysLTR1 and 2 in Maturating Lymphocytes of Hyperplasic Tonsils Compared to Peripheral Cells in Children
- Macrophage migration inhibitory factor and chemokine RANTES in young pediatric patients with congenital cardiac communications: relation to hemodynamic parameters and the presence of Down syndrome
- Time-to-treatment of diffuse large B-cell lymphoma in São Paulo
- Bortezomib (Btz) dose intensity is the strongest predictor for overall survival (OS) in mantle cell lymphoma (MCL) patients (Pts) not considered for transplantation, receiving frontline Btz plus rituximab, cyclosphosphamide, doxorubicin, and prednisone (VR-CAP) therapy in the phase 3 LYM 3002 study
- Angioimmunoblastic T-cell lymphoma and correlated neoplasms with T-cell follicular helper phenotype: from molecular mechanisms to therapeutic advances
- Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma
- Comparison between R-CHOP vs R-CHOP plus etoposide in untreated patients with primary mediastinal B-cell lymphoma: Preliminary findings
- 18 F-FDG pet interim and determination of cellular origin by immunohistochemistry identify a group of very good prognosis in patients with diffuse large B cell lymphoma in the rituximab era
- Follicular lymphoma: refining prognostic models and impact of pod-24 in clinical outcomes
Informações sobre o DOI: 10.1080/10428194.2017.1321750 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
